This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more

Bristol Myers Squibb (the manufacturer of Opdivo) offers the OPDIVO Co-Pay Card for commercially insured patients, which can significantly lower out-of-pocket costs.

For uninsured or underinsured patients who meet specific income criteria, manufacturer programs or independent charitable foundations (like the Patient Access Network Foundation) may provide the drug at no cost or offer grants to cover co-pays.

For older adults or low-income individuals, government programs often cover a large portion of Opdivo costs, typically under Medicare Part B since the drug is administered in an outpatient clinical setting. Step 4: Sourcing and Administration

Opdivo is a groundbreaking immunotherapy drug that has revolutionized cancer treatment by helping the body’s own immune system detect and destroy cancer cells. However, because it is a specialized biologic medication designed to treat complex conditions like melanoma, lung cancer, and renal cell carcinoma, "buying" Opdivo is not a standard retail transaction. Instead, acquiring Opdivo is a highly regulated, multi-step medical process that integrates clinical evaluation, insurance navigation, and specialized distribution. Step 1: Clinical Evaluation and Prescription

If the oncologist determines that Opdivo is the appropriate course of action, they will write a prescription. This prescription is not handed to the patient to take to a local drugstore; rather, it is sent directly to a hospital pharmacy or a specialized infusion center. Step 2: Insurance Verification and Authorization

Most insurance companies require "prior authorization" before they agree to cover Opdivo. The oncologist’s office must submit medical records proving that the treatment is medically necessary for the patient's specific condition.